Compare DSWL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | VERU |
|---|---|---|
| Founded | 1987 | 1971 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 41.9M |
| IPO Year | 2000 | 1996 |
| Metric | DSWL | VERU |
|---|---|---|
| Price | $2.88 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 5.5K | ★ 211.4K |
| Earning Date | 11-16-2026 | 12-16-2026 |
| Dividend Yield | ★ 7.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $2.05 |
| 52 Week High | $4.06 | $7.33 |
| Indicator | DSWL | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 40.22 |
| Support Level | N/A | $2.11 |
| Resistance Level | $3.48 | $2.68 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 5.02 | 25.75 |
Deswell Industries Inc comprise the manufacturing and sales of injection-molded plastic parts and components and electronic products assembling. The manufacturing activities are subcontracted to operating in the Macao Special Administrative Region (Macao) of the PRC. It produce a wide variety of plastic parts and components that are used in the manufacture of consumer and industrial products, using different plastic injection technologies, such as film injection, integrated injection and insert injection. It has two segments: plastic injection molding and electronic products assembling. It has generates majority of profit from Electronic Segment. It has presence in China, United States, Europe, Hong Kong, United Kingdom, Canada, and Others of which majority of sales is from China.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.